DBV Technologies (DBVT) Return on Capital Employed (2021 - 2026)
DBV Technologies (DBVT) posted quarterly Return on Capital Employed of 93.35% for Q2 2026, up 16288.0% year-on-year from N/an in Q2 2025, and down 9.94% on a QoQ basis from 84.91% in Q1 2026.
DBV Technologies (DBVT) Return on Capital Employed (2021 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Return on Capital Employed for 6 consecutive years, with 93.35% the latest figure, recorded in Q2 2026.
- Quarterly Return on Capital Employed rose 16288.0% year-over-year to 93.35% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 93.35% (up 16288.0% YoY) and the FY2025 annual result came in at 160.4%, down 3529.0% from the prior year.
- Return on Capital Employed retreated to 93.35% in Q2 2026 per DBVT's latest filing, from 84.91% in the prior quarter.
- Over the last five years, Return on Capital Employed for DBVT reached as high as 30.27% in Q3 2022 and fell as low as 646.68% in Q1 2025.
- A 5-year average of 129.08% and a median of 82.86% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 58592 bps — and 2026, when it surged 56178 bps.
- Year by year, Return on Capital Employed stood at 44.37% in 2022, then declined by 16 bps to 51.28% in 2023, then plunged by 371 bps to 241.78% in 2024, then surged by 47 bps to 128.86% in 2025, then gained by 28 bps to 93.35% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 93.35%, 84.91%, and 128.86% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -93.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -93.35% |
| Mar 31, 2026 | -84.91% |
| Dec 31, 2025 | -128.86% |
| Sep 30, 2025 | -162.42% |
| Jun 30, 2025 | -256.23% |
| Mar 31, 2025 | -646.68% |
| Dec 31, 2024 | -241.78% |
| Sep 30, 2024 | -143.93% |
| Jun 30, 2024 | -90.19% |
| Mar 31, 2024 | -60.76% |
| Dec 31, 2023 | -51.28% |
| Sep 30, 2023 | -59.54% |
| Jun 30, 2023 | -53.31% |
| Mar 31, 2023 | -48.82% |
| Dec 31, 2022 | -44.37% |
| Sep 30, 2022 | -30.27% |
| Jun 30, 2022 | -45.91% |
| Mar 31, 2022 | -80.80% |
| Dec 31, 2021 | -77.39% |
| Sep 30, 2021 | -82.46% |